Strategic Acquisition Claret Medical has been acquired by Boston Scientific, signaling a strong channel expansion and potential for integrated sales motions with a larger distributor and existing customer base.

Cerebral Protection Leader SENTINEL CPS is a pioneering embolic protection device with a dominant European market share and FDA-cleared status, presenting a compelling cross-sell opportunity into Boston Scientific’s TAVR portfolio.

Growth through TAVR The product uniquely protects against peri-procedural strokes during TAVR, aligning with rising TAVR adoption trends and demand for neuroprotection in interventional cardiology.

Financial Alignment With limited current revenue (<$1M) and strategic backing from Boston Scientific, there is potential to accelerate demand generation, clinical uptake, and payer discussions leveraging deeper resources.

Global Footprint & Partnerships Europe has a ~97% market share and there are existing relationships with investors and distributors; opportunities exist to leverage Boston Scientific’s global network to scale commercialization and access new markets.